Astrazeneca Pharma gets import and market permission for Selumetinib 10 Mg & 25 Mg Capsule

27 Sep 2021 Evaluate

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule. Selumetinib 10 mg & 25 mg capsule is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN). The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma I Share Price

8417.50 63.05 (0.75%)
20-Mar-2026 13:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1780.35
Dr. Reddys Lab 1305.25
Cipla 1259.40
Zydus Lifesciences 895.90
Lupin 2336.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×